

AGENDA
Saturday - June 10, 2017

7:15 am – 8:00 am	Registration & Breakfast
8:00 am – 8:05 am	Welcome & Opening Remarks - <i>Aaron Sasson, MD, FACS</i>
8:05 am – 9:00 am	SESSION 1: Detection & Diagnostics
8:05 am – 8:15 am	General Overview – <i>Aaron Sasson, MD, FACS</i> <ul style="list-style-type: none"> • Increased Incidence & Epidemiologic Characteristics of NETs • Heterogeneity and Subtypes of Neuroendocrine Tumors • Natural History and Patterns of Disease Progression
8:15 am – 8:30 am	Principals of Pathology for Diagnosis – <i>Jela Bandovic, MD</i> <ul style="list-style-type: none"> • Immunohistochemistry • Differentiation & Grade – Importance for Predictive & Prognostic Purposes • Mitotic Rate & KI67
8:30 am – 8:50 am	Perspectives in Diagnosis – <i>Michelle Kim, MD, MSc, AGAF, FASGE</i> <ul style="list-style-type: none"> • Clinical Presentation • Differential Diagnosis: Common Misdiagnosed Conditions & Pitfalls <ul style="list-style-type: none"> ○ IBS, IBD, ZES, Ulcer, or NET? ○ Biochemical Testing • Endoscopic Staging <p style="text-align: center;">Q & A (10 min)</p>
9:00 am – 9:45 am	SESSION 2: Imaging Modalities and Applications in the Diagnosis & Management of NETs
9:00 am – 9:15 am	Optimizing Anatomical/Cross-sectional Imaging of NETs – <i>Matthew Barish, MD, FACR</i> <ul style="list-style-type: none"> • Choosing the Right Modality & Sequence • Staging & Treatment Selection <ul style="list-style-type: none"> ○ Monitoring Response to Therapy ○ Assessing Tumor Response to Therapy: Role of Quantitative Imaging
9:15 am – 9:35 am	Molecular Imaging for Diagnostics – <i>Robert Matthews, MD</i> <ul style="list-style-type: none"> • Functional Imaging: Role & Limitations <ul style="list-style-type: none"> ○ SPECT/CT, PET/CT & PET/MRI • Diagnosis & Staging <ul style="list-style-type: none"> ○ Gallium 68 dotatate ○ Octreoscan ○ ¹⁸F-FDG: fluorodeoxyglucose ¹¹C-HTTP: hydroxytryptophan ¹⁸F-DOPA: dihydroxyphenylalanine ○ ¹³¹I or ¹²³I-MIBG • Imaging Algorithm, Appropriate Use Criteria & NCCN Guidelines • Evolving Role of Nuclear Medicine Imaging & Current Clinical Trials <p style="text-align: center;">Q & A (10 min)</p>
9:45 am – 10:00 am	BREAK
10:00 am – 10:50 am	SESSION 3: First Line Therapy for NETs - Surgical Removal of Primary Tumors
10:00 am – 10:20 am	Pancreatic NETs - <i>Aaron Sasson, MD, FACS</i> <ul style="list-style-type: none"> • Functional vs Nonfunctional <ul style="list-style-type: none"> ○ Role of Resection. Vascular Invasion, Size (2 cm cutoff?) • Surgical Options - Enucleation, Segmental Resections, Distal Pancreatectomy, Pancreaticoduodenectomy (open vs laparoscopic) Splenopancreatectomy <ul style="list-style-type: none"> ○ Nutritional, Enzyme & Vitamin Support • Should Liver Lesions be Resected at Time of Primary Tumor Surgery?
10:20 am – 10:40 am	Intestinal NETs – <i>Joseph Kim, MD, FACS</i> <ul style="list-style-type: none"> • Work-up – Pathology, Imaging & Biomarkers (specifics per location) • Gastric - Type 1, 2 & 3 • Small Bowel <ul style="list-style-type: none"> ○ Multi Centric Tumors, Segmental Resection with Nodal Clearance Mesenteric Nodal Disease (SMA/SMV) • Appendiceal <ul style="list-style-type: none"> ○ Consideration for Right Hemicolectomy • Prophylactic Cholecystectomy • Peritoneal Disease • Colon & Rectal <ul style="list-style-type: none"> ○ Endoscopic (Tattoo), Transanal Excision, Surgical Resection <p style="text-align: center;">Q & A (10 min)</p>

10:50 am – 11:40 am	SESSION 4: Management of Hepatic Metastases Surgical & Regional Approaches
10:50 am – 11:10 am 11:10 am – 11:30 am	<p>Surgical & Regional Approaches</p> <ul style="list-style-type: none"> • Liver Surgery – <i>Steven K. Libutti, MD, FACS</i> <ul style="list-style-type: none"> ○ Resection ○ Cytoreduction – Optimal Target – 90% vs 70%, Contraindications • Interventional Radiology – <i>Valmore Suprenant, MD</i> <ul style="list-style-type: none"> ○ Patient Selection ○ Embolotherapy & Ablation ○ Integrating Liver- Directed into the Therapeutic Algorithm ○ Future Directions, Considerations & Clinical Trials <p style="text-align: center;"><i>Q & A (10 min)</i></p>
11:40 am – 12:10 pm	SESSION 5: Treatments for Symptom Control Hal Gerstein, MD
	<p>Carcinoid Syndrome Symptom Control</p> <ul style="list-style-type: none"> • Somatostatin Analogs (SSA's – octreotide, lanreotide) <ul style="list-style-type: none"> ○ Mechanisms of Action ○ Long Term Use • Refractory Diarrhea <ul style="list-style-type: none"> ○ Escalate SSA's? ○ Telotristat Ethyl ○ Is There a Role for Alpha Interferon? <p>Other Symptom Control</p> <ul style="list-style-type: none"> • Managing Persistent/Recurrent Diarrhea Not Associated with Carcinoid Syndrome <ul style="list-style-type: none"> ○ Pancreatic Insufficiency from SSA Use (Pancreatic & Digestive Enzymes) ○ Biliary Salt Malabsorption, Short Gut Syndrome, Bacterial Overgrowth) <p style="text-align: center;"><i>Q & A (10 min)</i></p>
12:10 pm – 12:50 pm	LUNCH
12:50 pm – 1:25 pm	SESSION 6: Therapeutic Options for the Management of Progressive Disease Minsig Choi, MD
	<p>Inhibition of Tumor Progression</p> <ul style="list-style-type: none"> • SSA's Role in Disease Stabilization <ul style="list-style-type: none"> ○ Use in Asymptomatic Patients – When Should SSA Treatment Be Initiated? <p>GI & Lung NETs</p> <ul style="list-style-type: none"> • mTOR Inhibition <ul style="list-style-type: none"> ○ RADIANT – 4 (Everolimus) • Anti-angiogenic Therapy <p>Pancreatic NETs</p> <ul style="list-style-type: none"> • Targeted Therapies <ul style="list-style-type: none"> ○ Tyrosine Kinase Inhibitors (Sunitinib) ○ mTOR Inhibition: RADIANT - 3 (Everolimus) • Chemotherapy <p>Poorly Differentiated NETs</p> <ul style="list-style-type: none"> ○ Heterogeneity ○ Platinum based Therapies ○ Temozolimide - based treatments <p>Current Clinical Trials</p> <p style="text-align: center;"><i>Q & A (10 min)</i></p>
1:25 pm – 2:00 pm	SESSION 7: Radiolabeled Peptides - An New Era in Treatment of NETs Ghassan El-Haddad, MD
	<p>Peptide Receptor Radionuclide Therapy (PRRT)</p> <ul style="list-style-type: none"> • Background & European Clinical Experience • Selection Criteria • NETTER 1 Trial – Study Objectives & Design • Preventing Toxicities & Nausea • Where Should PRRT Be in the Treatment Paradigm? • Get Prepared • Future Directions & Current Clinical Trials <p style="text-align: center;"><i>Q & A (10 min)</i></p>
2:00 pm – 2:15 pm	Closing Remarks & Adjourn